Kinathera
Kinathera is a seed stage preclinical biotech on a mission to develop unique series of newly patented, orally delivered small chemical molecules to treat patients suffering from immuno-inflammatory disorders. Selective inhibition of our most advanced target, simultaneously: 1, blocks intracellular cascade of the ICOS receptor which control maturation of the humoral response and 2, inhibits type 1 interferon production, a master regulator of BAFF expression and demonstrated component of auto-immune diseases. Activity of Kinathera’s compound on two key immune paths promises enhanced control of hyperactive immune reaction in auto immune or GvHD indications.
7-day free trial · no credit card
Verified contacts
4
available on Kipplo
LinkedIn employees
1 to 10
headcount range
Open roles
—
no listings
Distinct roles
4
indexed titles
Tech stack
0
tools in use
Monthly traffic
—
organic / mo
Sign up free to see all 4 verified contacts at Kinathera
Free for 7 days · 50 credits · no card · only pay for verified records.
Decision-makers and verified team members
4 contacts with verified email or phone · masked until revealed.
No verified contacts on record for this company yet.
Top roles at Kinathera
4 distinct titles indexed · top 4 shown.
- 1ceo and founder
- 1chief development officer (cdo)
- 1in vivo pharmacology manager
- 1office manager
Sign up to unlock all 4 contacts at Kinathera
Free for 7 days · 50 credits · no card · only pay for verified records.
Sign up to reveal 4 verified contacts at Kinathera
7-day trial · no credit card · cancel anytime · only pay for verified records.
Trusted by sales, marketing, and GTM engineering teams.